Elizabeth Thomas

Elizabeth joined ImaginAb in 2021 as the regulatory affairs lead and is responsible for managing and leading the overall regulatory strategy for the company’s development programs.

Elizabeth is passionate about targeted cancer therapeutics that selectively attack cancer cells while sparing normal healthy cells and is excited about the promise of the ImaginAb’s precision technology poised to deliver a novel biologic imaging agent in the radiopharmaceutical area that selectively detects target cells.

Prior to her current role, Elizabeth provided regulatory contributions developing strategy and submissions for IND stage products as Associate Product Development Champion at Facet Life Sciences. Also in her prior roles, Elizabeth was Associate Director (Drug Product) at Lexicon Pharmaceuticals responsible for formulation and analytical activities of preclinical to commercial stage products. Elizabeth held Principal and Senior Scientist positions at Pfizer (formerly Wyeth) responsible for analytical development of oncology drugs on the immunoconjugate platform where she led multiple transition efforts into new technologies, implementations and transfers while contributing to manufacturing activities, clinical administration and BLA submissions.

Early in her career, Elizabeth worked on developing in vitro hemostasis diagnostics products as an R&D scientist in Instrumentation Laboratory. All through her 20-year career in the medical device/biopharmaceutical career, Elizabeth had overall responsibility for authoring and providing input to regulatory filings in her areas. Elizabeth also worked as adjunct faculty teaching science subjects at the Lonestar Community College.

In her free time, Elizabeth enjoys rearranging the backyard, listening to 60s, 70s, 80s music, and occasionally choreographing dances or directing church plays.